Jiangsu Hengrui Pharmaceuticals Co., Ltd.SSE: 600276

(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance by the EMA of the Application for Drug Marketing Authorization

· Issued by Jiangsu Hengrui Pharmaceuticals Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 600276 · · 3 pages · Chinese and English

Summary by 6ix AI

Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced that the European Medicines Agency has accepted its application for marketing authorization of Fuzuloparib capsules, marking the company's second innovative drug submission in the EU. The announcement includes details about the drug's clinical trial, which demonstrated significant efficacy in treating metastatic castration-resistant prostate cancer compared to a placebo. The company warns that the approval process still involves uncertainties and encourages investors to be cautious regarding potential risks.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/600276jiangsu-hengrui-pharmaceuticals-co-ltdindicative-announcement-on-acceptance-by-the-ema-of-the-application-for-drug-marketing-authorization

Release

Indicative Announcement on Acceptance by the EMA of the Application for Drug Marketing Authorization

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix

Story so far

Earlier from Jiangsu Hengrui Pharmaceuticals

Later from Jiangsu Hengrui Pharmaceuticals

All Jiangsu Hengrui Pharmaceuticals news releases